ME2 Meet the expert
New treatment approaches for idiopathic pulmonary fibrosis - FULLY BOOKED
Translational
Registration for this session is additional to the congress registration fee and is €100 on site, €90 standard or €70 for early bird registration.
Aims : Access educational materials here
To review the drug development landscape for idiopathic pulmonary fibrosis (IPF) in the light of the newly approved anti-fibrotic drugs pirfenidone and nintedanib; and to discuss the preclinical, methodological, and clinical challenges in IPF drug development.
Target audience :
Clinician, Pulmonologist, Researcher, Respiratory physician, Scientist, Trainee
13:00
New treatment approaches for IPF
L. Richeldi(Roma, Italy)
COI
1
1421
13:40
Interview by a junior member
N. Kahn(Heidelberg, Germany)
COI
2
. . .